Intensity Therapeutics Inc Dossier - Source-backed chat

Intensity Therapeutics Inc

INTSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.35

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.21Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $10.5M

Enterprise Value $1.1M

Shares Outstanding 3.3M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Intensity Therapeutics is a late-stage clinical biotechnology company pioneering a novel intratumoral cancer therapy, INT230-6, designed to induce localized tumor necrosis and stimulate a systemic adaptive immune response. While preliminary Phase 2 data in triple-negative breast cancer (TNBC) from the INVINCIBLE-4 study are highly encouraging—demonstrating a 71.4% pathological complete response (pCR) rate compared to 33% for standard of care alone—the company faces severe capital constraints. The Phase 3 INVINCIBLE-3 sarcoma trial remains paused for new enrollments due to funding limitations, and there is substantial doubt regarding the company's ability to continue as a going concern. Although a $60 million ATM facility is in place, utilizing it at current depressed valuations would cause massive shareholder dilution. Consequently, a Hold recommendation is warranted until the company secures non-dilutive financing or a strategic partnership to resume its Phase 3 program.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.00

Mean target$21.80

High · most bullish analyst$32.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company fails to secure additional funding or a strategic partner, preventing the resumption of the Phase 3 INVINCIBLE-3 trial. Dosing modifications in the INVINCIBLE-4 study fail to resolve localized skin irritation, leading to regulatory holds. Severe dilution from aggressive ATM utilization at low share prices decimates equity value, ultimately forcing a restructuring or distressed asset sale.

Base CaseCentral scenario

The company successfully resumes limited enrollment in the Phase 3 INVINCIBLE-3 sarcoma trial by Q3 2026 using tactical ATM issuances. Phase 2 INVINCIBLE-4 TNBC trial enrollment continues steadily toward its late-2027 completion target. The company maintains its cash runway into early 2027, eventually securing a regional licensing partnership that provides non-dilutive upfront capital, validating the DfuseRx platform and stabilizing the stock.

Bull CaseUpside scenario

The bull case is centered on the clinical potential of INT230-6, which has demonstrated strong efficacy in early trials, including a 75% disease control rate in advanced solid tumors and a 71.4% pathological complete response (pCR) in early-stage triple-negative breast cancer. The platform's unique intratumoral delivery technology (DITPA) allows direct tumor killing while inducing a systemic immune response (abscopal effect). If the company successfully secures funding to complete its Phase 3 soft tissue sarcoma trial and expands its breast cancer program, it could capture a significant share of difficult-to-treat oncology markets, driving exponential valuation growth from its micro-cap base.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong preliminary efficacy signal in TNBC with a 71.4% pCR rate in Cohort A of the INVINCIBLE-4 study compared to 33% in the standard of care arm.
Favorable safety profile with 44% fewer Grade 3 or higher adverse events observed in the INT230-6 combination cohort compared to standard of care alone.
Proprietary DfuseRx platform technology enables direct intratumoral delivery of potent cytotoxic agents (cisplatin and vinblastine) without systemic immunosuppression.
Regained compliance with Nasdaq's minimum bid price requirement in March 2026, stabilizing its listing status.

Key Investment Risks

Substantial doubt exists about the company's ability to continue as a going concern, with a cash balance of $10.2 million as of March 31, 2026.
The lead Phase 3 clinical trial (INVINCIBLE-3) in soft tissue sarcoma is currently paused for new patient enrollment due to funding constraints.
High risk of severe equity dilution due to reliance on a $60 million ATM facility to fund expensive late-stage clinical trials.
Clinical development risks, including potential safety issues such as localized skin irritation that previously prompted a temporary enrollment pause.

Thesis Invalidation Triggers

Failure to resume patient enrollment in the INVINCIBLE-3 trial by the end of 2026.
A regulatory clinical hold placed on the INVINCIBLE-4 study due to unresolved safety or toxicity issues.
Inability to secure a strategic partnership or non-dilutive financing before the end of 2026, leading to severe liquidity distress.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.